Kaufmann Stefan H E
Stefan H. E. Kaufmann is at the Max Planck Institute for Infection Biology, Department of Immunology, Schumannstrasse 21-22, 10117 Berlin, Germany.
Nat Rev Immunol. 2006 Sep;6(9):699-704. doi: 10.1038/nri1920. Epub 2006 Aug 18.
The design of tuberculosis vaccines has entered a new era. Although several new vaccine candidates will pass Phase I clinical trials within the next year, I believe that the most effective vaccination strategy will be to combine different vaccine candidates and to use a prime-boost approach. This strategy, however, would require several years of iterative vaccine trials, unless the process is expedited by the identification of reliable biomarkers for assessing vaccine efficacy. In this Essay, I briefly summarize past and present attempts to develop a vaccine against tuberculosis, and I describe, using imagined scenarios, the tuberculosis vaccination schemes that might become available from a large repertoire of candidate schemes in the near and distant future.
结核病疫苗的设计已进入一个新时代。尽管有几种新的候选疫苗将在明年内通过一期临床试验,但我认为最有效的疫苗接种策略将是把不同的候选疫苗结合起来,并采用初免 - 加强的方法。然而,除非通过识别用于评估疫苗效力的可靠生物标志物来加快这一进程,否则这一策略将需要数年的反复疫苗试验。在这篇文章中,我简要总结了过去和现在研发抗结核疫苗的尝试,并通过设想的情景,描述了在不久和遥远的未来可能从大量候选方案中出现的结核病疫苗接种方案。